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Infantile spasms (IS) is the most severe and common form of epilepsy occurring in the ﬁrst year of life. At least half of IS cases are
idiopathic in origin, with others presumed to arise because of brain insult or malformation. Here, we identify a locus for IS by high-
resolution mapping of 7q11.23-q21.1 interstitial deletions in patients. The breakpoints delineate a 500 kb interval within the MAGI2
gene (1.4 Mb in size) that is hemizygously disrupted in 15 of 16 participants with IS or childhood epilepsy, but remains intact in
11 of 12 participants with no seizure history. MAGI2 encodes the synaptic scaffolding protein membrane-associated guanylate kinase
inverted-2 that interacts with Stargazin, a protein also associated with epilepsy in the stargazer mouse.
The hemizygous microdeletion of a 1.5 Mb region of chro-
mosome 7q11.23 causes the neurodevelopmental disorder
Williams-Beuren syndrome (WBS [MIM 194050]). WBS is
characterized by numerous physical, cognitive, and behav-
ioral symptoms,1 but seizures have only rarely been re-
ported and were presumed to be unrelated to the deletion
of genes in the critical region.2 The typical WBS deletion
spans a common interval of between 26 and 28 genes,
because it arises due to unequal meiotic recombination
between highly similar ﬂanking nucleotide sequences.3
Larger WBS-associated deletions have been reported and
they often have one breakpoint that is similar to those as-
sociated with the common deletion. When the deletion
extends telomeric, a more severe phenotype with serious
impairments in cognitive function is typically observed4,5
and this is sometimes accompanied by infantile spasms.6–8
Infantile spasms (IS, also known as West syndrome) is
a disorder of the developing nervous system that begins
in the ﬁrst year of life, most commonly between 4 and 8
months of age.9 In approximately 50% of IS cases, the
spasms are a symptom of generalized brain disturbance, in-
cluding CNS infection10 and developmental brain abnor-
malities such as lissencephaly (LIS1 [MIM 607432]; LISX1
[MIM 300067]), focal cortical dysplasia,11 neurocutaneous
syndromes such as tuberous sclerosis (TS [MIM 191100])
and neuroﬁbromatosis (NF1 [MIM 162200]), incontinentia
pigmenti (IP [MIM 308300]),12,13 hypoxic ischemic en-
cephalopathy,14,15 or rare chromosomal or genetic abnor-
malities such as Down syndrome (DS [MIM 190685]),
ARX mutations (ISSX1 [MIM 308350]), and CDKL5 muta-
tions (ISSX2 [MIM 300672]).16,17 In all these etiologies, IS
is present in only a fraction of cases occurring as part of
a much larger spectrum of neurological symptoms.
Idiopathic IS accounts for the other half of the cases and
occurs in the absence of any brain malformation or neuro-
logical insult.11,12,18 IS is an epilepsy syndrome with a
seizure type characterized by clusters of ﬂexion jerks of
the neck, trunk, and extremities lasting 1–2 s occurring
throughout the day. These spasms have a distinctive
high-voltage, disorganized pattern on electroencephalo-
gram (EEG), called hypsarrhythmia, that is seen (in some
form) in approximately two thirds of cases of IS.19 IS is
associated with a signiﬁcant risk of mortality and morbid-
ity,20 and is usually treated with adrenocorticotropic hor-
mone or Vigabatrin, both of which are variably effective
and can have severe side effects.21 The characteristic hyp-
sarrhythmia pattern must be abolished if the prognosis is
to be improved, otherwise the immature brain appears to
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remain hyperexcitable and proper neurodevelopment is
impeded. Approximately 50%–60% of children with IS
will go on to develop other seizure types.22,23
Reportsof largerhemizygous chromosomedeletionsasso-
ciatedwith bothWBS and IS suggested that a locus for IS ex-
isted within band q11.23-q21.1 of chromosome 7, distal to
the region commonly deleted in WBS.6–8 In order to deter-
minewhether a novel locus for IS could be deﬁned,we iden-
tiﬁed 12 cases with interstitial deletions of 7q11.23-q21
from our Chromosome 7 Annotation Project clinical data-
base24 and another 16 cases from the literature with dele-
tions overlapping this same region.4–8,25–30 DNA samples
were available from the 12 new cases and from eight of
the cases from the literature.
In 12 cases where the availability of DNA and array tech-
nology allowed, wemapped the deletion boundaries by us-
ing comparative intensity analysis with single nucleotide
polymorphism (SNP) microarrays. For the remaining 8
cases with DNA available, deletion breakpoints were map-
ped by other methods (outlined in Table 1). The break-
points of cases from the literature where no DNA sample
was available were determined from the published data.
All protocols were approved by the Research Ethics Boards
of the institutions involved, and appropriate informed
consent was obtained from all human participants or their
guardians. For all participants, genomic DNAwas prepared
fromperipheral blood lymphocytes by standardmethodol-
ogies. Clinical descriptions of 16 cases have been published
previously.4–8,25–30 Additional cases described in this study
included twowith a diagnosis ofWBS, sevenwith a diagno-
sis of WBS plus IS, and three with a diagnosis of IS or other
seizure disorder without WBS. Clinical data for all subjects
with hemizygous 7q11.23-q21.1 deletions are presented in
Table 1.
To further deﬁne the breakpoints of the interstitial
7q11.23-q21.1 deletions and to establish copy number var-
iation (CNV) content in the rest of the genome, 12 of the
28 cases were genotyped with either Affymetrix Human
Mapping 500K or Genome-Wide Human SNP 6.0 Arrays
(Affymetrix Inc., Santa Clara, CA) according to the manu-
facturer’s instructions. CNV analysis of Affymetrix 500K
arrays was performed as described previously.31 Affymetrix
6.0 arrays were analyzed for CNV with a combination of
Partek Genomics Suite (Partek Inc., St Louis, MO) and
Affymetrix Genotyping Console (Affymetrix Inc.).
The CNVs identiﬁed in eachDNA sample were compared
with previously documented CNVs found in 1652 healthy
population controls31 and those in the Database of Geno-
mic Variants, a curated catalog of structural variations in
the human genome.32 All identiﬁed CNVs are presented
Table 1. Summary of Clinical Features in Participants with Deletions of Chromosome 7q11.23-q21.1
Case Ref. Gender
Deletion
Size (Mb)
Breakpoint
Mapping Clinical Description
1 TS M 3.4 Array, QPCR WBS with severe hypercalcemia
2,3,4 5 2M, 1F 2.4 FISH WBS with moderate MR (ref 5 cases 15481, 18393, 18317)
5 5/TS F 4.2 Array WBS with severe MR (ref 5 case 23162)
6 TS M 4.2 Array WBS with severe MR
7 5/TS F 4.3 QPCR WBS with severe MR (ref 5 case 29948)
8 4/TS F 4.2 Array WBS with periventricular heterotopia, severe MR, nonverbal
9 28 F 2.4–2.8 QPCR WBS cognitive-behavioral profile with moderate MR and autism spectrum disorder
10 7/TS M 4.4 Array, QPCR WBS with IS (variation form of hypsarrhythmia), severe developmental delay
11 TS F 6.7 QPCR WBS with IS (hypsarrhythmia) at 4 months and severe global developmental delay
12 TS M 5.5 QPCR WBS with severe delays, IS, myoclonic, and tonic seizures
13 TS M 11–12.5 QPCR WBS with IS, hypotonia, severe PMD, nonverbal, Wolff-Parkinson-White syndrome
14 TS F 10 QPCR WBS with IS, hypoglycemia, contractures, severe PMD
15 TS M 8.3 Array, QPCR WBS with IS and focal seizures at 5 months, severe MR
16 5/TS M 11 Array WBS with IS, severe MR (ref 5 case 20495)
17 6/TS M 17 Array, QPCR WBS with IS (hypsarrhythmia) at 2 months and severely retarded PMD
18 TS M 19.6 Array, QPCR WBS with EEG abnormalities, severe PMD, marked hypotonia
19 8 F >9 MMA WBS with petit mal seizures, macrocephaly, severe MR, and minimal speech
20 TS F 17 Array, QPCR WBS with IS, minimal development and blindness
21 TS M 26 QPCR IS, childhood epilepsy, optic nerve hypoplasia, cerebral palsy, severe MR, nonverbal
22 TS M 11.5 Array, QPCR Myoclonus epilepsy, developmental delay, nonverbal
23 27 F 16 MMA IS, PMD, and dysmorphism
24 TS F 15–20 MMA Seizure disorder age 7 years, nonverbal
25 30/TS F 19 Array, QPCR IS, severe MR, microcephaly, scoliosis, dysmorphism, and ectrodactyly
26 29/TS F 3 Array, QPCR Growth retardation, MR, clinodactyly, mild spasticity, hypersensitivity to noise
27 26 F 16 Array Growth retardation, severe MR, microcephaly, complete hearing loss
28 25 M 12–14 FISH Microcephaly, short stature, myoclonus-dystonia syndrome
(e-sarcoglycan deletion), developmental delay
Abbreviations: TS, this study; WBS, Williams-Beuren syndrome; MR, mental retardation; PMD, psychomotor delay; IS, infantile spasms; ns, not specified; M,
male, F, female; Array, Affymetrix Human Mapping 500K or Genome-Wide Human SNP 6.0 Arrays; FISH, fluorescent in situ hybridization; QPCR, quantitative
real-time PCR; MMA, microsatellite marker analysis.
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Figure 1. Summary of Interstitial Deletions of 7q11.23-q21.1 in Cases with and without Infantile Spasms
Deletion mapping of cases 1 to 28 defines a critical region for infantile spasms (IS) spanning part of MAGI2. Quantitative real-time PCR
amplimers are indicated below the MAGI2 gene along with the two known transcriptional start sites for the a and b isoforms of the pro-
tein. MAGI2 is partially or wholly deleted in 12 cases with IS, and another three with childhood epilepsy (cases 11–25). Cases 1–9 and 27–
28 have interstitial deletions that are proximal and distal, respectively, to MAGI2 and have had no diagnosis of epilepsy. Case 10 has
a diagnosis of IS but is not deleted for MAGI2. Case 26 is deleted for part of MAGI2 but has not had any diagnosis of epilepsy.
Chromosome deletions are represented by bars, below a map of genes from the 7q11.23-q21.11 region. Black bars represent deletions in
cases with documented seizures, and white bars represent deletions in cases without documented seizures. Grey bars indicate breakpoints
that have not been refined.in Table S1 available online. Comparative intensity analysis
enabled themappingof the 7q11.23-q21.1 deletionbound-
aries in each sample, to within approximately 10 Kb.When
a deletion breakpoint laywithin the low copy repeats ﬂank-
ing the WBS region, it was impossible to determine the
breakpoint location because of the presence of multiple
copies of SNPs from within these low copy repeats.
Conﬁrmation of the array data and reﬁning of the break-
points within and aroundMAGI2 was carried out by quan-
titative real-time PCR analysis with the 7900HT genetic
analyzer (Applied Biosystems, Foster City, CA). The total
volume was 11 ml and reactions were performed in tripli-
cate, with 5 ng of template for 40 cycles of ampliﬁcation
via Power SYBR master mix (Applied Biosystems). The
DNA copy number of each test sequence was obtained
from a calibration curve that assumes the reference ge-
nome is present in two copies at that site. Genomic ratios108 The American Journal of Human Genetics 83, 106–111, July 20were determined by comparing absolute copy number of
the test sequences to the reference gene HMBS. Primer po-
sitions are shown in Figure 1 and primer sequences in Table
S2. Quantitative real-time PCR analysis of MAGI2 exon 1
and exon 21 was carried out on all available DNA samples
(cases 1, 5–8, 10–18, 20–22, 24–26), and breakpoints for
critical cases were further reﬁned with additional primer
pairs (Tables S2 and S3).
We found deletions of 7q11.23-q21.1 ranging from
2.4Mbtomore than25Mb in size (Figure1 andTable 1). Sei-
zure historywas obtained for all cases and genotype-pheno-
type correlationwas performed on the basis of the presence
or absenceof ISor other formsof seizure activity.Wedeﬁned
a smallest region of overlap associated with IS of approxi-
mately 500 kb, spanning part of the 1.4 Mb membrane-
associated guanylate kinase inverted-2 gene (MAGI2 [MIM
606382]). All but one of 16 individuals with a chromosome08
7 deletion and ISweremissing all or part ofMAGI2, whereas
only one of 11 individuals with a chromosome 7 deletion
and no seizure history was missing any part of MAGI2 (p
< 0.001; chi square, 1 df). There are no reported CNVs
that span exons ofMAGI2, further supporting the hypoth-
esis that hemizygosity for this gene results in a phenotypic
effect.32 Based on the available evidence, we propose
MAGI2 as a dominant locus for IS.
All the cases with IS had deletions spanning multiple
genes, suggesting that IS could arise as the consequence
of haploinsufﬁciency for more than one gene, or alterna-
tively as a result of position effects mediated by the large
chromosomal deletions. However, the range of deletion
sizes and the location of the deletions themselves argue
against these hypotheses. The deletions that include
MAGI2 extend either distal or proximal to the gene. Al-
though some deletions extend in both directions, there
are several deletions that extend in opposite directions so
that they include completely different gene sets (Figure 1;
cases 11–14 versus cases 23–25), making a two-gene hy-
pothesis extremely unlikely. The effect of the deletion itself
also seems an unlikely explanation for IS, because there are
individuals who have large deletions outside the critical in-
terval but do not exhibit seizures or associated phenotypes
(Figure 1; cases 1–9, 27, 28).
Only a single participant with WBS and well-docu-
mented IS harbored a deletion that did not span any part
of MAGI2 (case 10).7 However, because the etiology of IS
is heterogeneous, it is possible that the IS in this individual
is unrelated to their chromosome 7 deletion, particularly
because their deletion is very similar to ﬁve other cases
without IS (Figure 1; cases 5–9). Array analysis did not re-
veal any previously unreported copy number variant that
could have contributed to the phenotype in this individual
(Table S1). In addition, a single case harbored a deletion
that encompassed part of MAGI2, without a documented
occurrence of IS (case 26).29 This woman carries a 3 Mb
de novo deletion and was referred for genetic testing at
the age of 10.5 years because of nonspeciﬁcmental retarda-
tion. Although she has had no documented seizure activity
since the age of 10.5 years, her early clinical history was
not available so we cannot exclude the possibility that
she may have had earlier episodes of epilepsy or IS.
MAGI2 (also known as S-SCAM, synaptic scaffolding
molecule) was originally characterized as a scaffold protein
interacting with N-methyl-D-aspartic acid (NMDA) recep-
tors at excitatory synapses in the brain, its predominant
site of expression,33 but has since been shown to interact
with many different proteins pre- and postsynaptically
and at both excitatory and inhibitory synapses.34 Perhaps
the most intriguing interaction of MAGI2 is that with star-
gazin,34 the protein mutated in the stargazermouse, one of
the ﬁrst and best characterizedmousemodels of epilepsy.35
stargazer mice have impaired a-amino-3-hydroxy-5-
methyl-4-isoxazole propionic acid (AMPA) receptor trans-
port through the endoplasmic reticulum and cis-Golgi
compartments and lack functional AMPA receptors.36ThMAGI2 comprises a guanylate kinase domain, two WW
domains, and ﬁve PDZ domains. At least two isoforms
have been identiﬁed in humans, the largest (a) with an
additional N-terminal PDZ domain, and the other (b)
with a transcriptional start site in the alternative exon
2a.37 A recent mouse model lacking the longest, a isoform
of MAGI2 exhibited no obvious phenotype in the hetero-
zygous state, and homozygous mutants died at birth;38
however, the MAGI2 b isoform was intact in these mice
and every one of the documented protein interactions
occurs via domains shared by both isoforms. All of the
individuals with IS and disruption of MAGI2 reported in
the present study (cases 11–25) had deletions that would
result in the hemizygous disruption of both isoforms of
the protein, suggesting that IS results from a decrease in
protein interactions involving the common domains of
MAGI2, i.e., the WW domains and/or the ﬁve PDZ
domains.
The identiﬁcation of this locus for IS has implications for
the clinical management of individuals with WBS and
large deletions of 7q11.23-q21.1. Infants with WBS who
have deletions that extend to MAGI2 present with addi-
tional clinical features to those found in individuals with
the classic deletion (Table 1). These children exhibit very
delayed motor and developmental milestones compared
to children with typical WBS, often in combination with
hypotonia and severe intellectual disability. Their progno-
sis is also complicated by the presence of IS that may fur-
ther impact upon their neurological development. A longi-
tudinal study of the outcome of these individuals would
determine the extent and severity of their developmental
impairment and help to establish some prognostic guide-
lines for other families of newly diagnosed children with
similar deletions.
Although approximately 40% of human epilepsy is esti-
mated to be genetically determined,39 only a small fraction
of causative genes have been identiﬁed and almost all in
families exhibiting rare forms of epilepsy inherited in
a Mendelian fashion. To date, practically all these known
genes code for ion channels.40 The identiﬁcation of hemi-
zygosity for the postsynaptic scaffolding protein MAGI2
as a cause of IS sheds new light on the genetic etiology of
epilepsy and suggests that other proteins that regulate
the trafﬁcking, distribution, or function of the glutamate
receptors are attractive candidates for involvement in
human epilepsy. The postsynaptic density is comprised
of more than 100 proteins, offering numerous avenues
by which to disrupt the proper function of the synapse.
Further research will be needed to establish exactly how
MAGI2 hemizygosity leads to IS and whether the spasms
are truly idiopathic when associated withMAGI2 genemu-
tations rather than interstitial chromosome deletions. The
identiﬁcation of a causative gene should allow the devel-
opment of a genetic mouse model of IS and eventually
lead to the development and testing of targeted, effective
medications for this severe epilepsy, both in its isolated
form and in children with WBS.e American Journal of Human Genetics 83, 106–111, July 2008 109
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